Comparison of three common whole blood platelet function tests for in vitro P2Y12 induced platelet inhibition
| Autor: | Torben Pottgiesser, Daniel Duerschmied, Jan Hartmann, Christoph Bode, Hardean E. Achneck, João D. Dias |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Platelets
Comparative Effectiveness Research Ticagrelor medicine.medical_specialty Platelet Function Tests Coefficient of variation Context (language use) 030204 cardiovascular system & hematology Gastroenterology Article 03 medical and health sciences 0302 clinical medicine P2Y12 Internal medicine Humans Medicine Platelet Diagnostic 030212 general & internal medicine Blood Coagulation EC50 Whole blood Coagulation business.industry Hematology Repeatability Healthy Volunteers Point-of-Care Testing Purinergic P2Y Receptor Antagonists TEG® Platelet function Drug Monitoring Cardiology and Cardiovascular Medicine business Platelet Aggregation Inhibitors medicine.drug |
| Zdroj: | Journal of Thrombosis and Thrombolysis |
| ISSN: | 1573-742X 0929-5305 |
| DOI: | 10.1007/s11239-019-01971-1 |
| Popis: | In the context of interventional cardiology, platelet function testing may identify patients treated with P2Y12-inhibitors at an increased risk of mortality, thrombosis and bleeding. Several whole blood point-of-care platelet function analyzers are available; however, inter-device differences have not been examined systematically. To compare three platelet function tests under standardized in vitro conditions. Healthy volunteer (n = 10) blood samples were spiked with increasing concentrations of ticagrelor (0–7500 ng/mL) and/or ASA (0–3280 ng/mL), measured on three platelet function analyzers (TEG®6s, Multiplate®, and VerifyNow®) and respective Effective Concentration (EC) levels EC10, EC50 and EC90 were calculated. Repeatability was assessed in a separate group of pooled blood samples (n = 10) spiked with ticagrelor at EC10, EC50 and EC90. ASA had no impact on ADP-activated channels for all three devices. TEG®6s was able to distinguish (p ≤ 0.05) between all ticagrelor EC zones; VerifyNow® and Multiplate® were able to distinguish between three and two zones, respectively. Multiplate® showed the largest window between EC10 and EC90 (19–9153 ng/mL), followed by TEG®6s (144–2589 ng/mL), and VerifyNow® (191–1100 ng/mL). Drug effect models distribution of disagreements were identified for TEG®6s (5.0%), VerifyNow® (8.3%), and Multiplate® (13.3%). TEG®6s showed the smallest average coefficient of variation between EC conditions (5.1%), followed by Multiplate® (14.1%), and VerifyNow® (17.7%). Linear models could be generated between TEG®6s and Multiplate®, but not VerifyNow®. Significant differences were found between whole blood point-of-care platelet function analyzers and the clinical impact of these differences needs to be further investigated. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink